{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-060505","form_type":"8-K","ticker":"LFST","cik":"0001845257","company_name":"LifeStance Health Group, Inc.","filed_at":"2023-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.999203+00:00","generated_at":"2026-06-08T10:49:08.403863+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"LifeStance Q3 revenue up 21% to $262.9M, net loss widens to $61.6M, raises FY guidance midpoints","bullets":["Revenue $262.9M (+21% YoY); clinicians up 18% to 6,418 with record organic recruiting.","Net loss $61.6M vs $37.9M, driven by class action settlement and stock-based comp.","Adjusted EBITDA $14.6M (5.6% of revenue) vs $15.4M (7.1%) last year.","Raising FY 2023 guidance: revenue $1.03-1.04B, Center Margin $292-300M, Adjusted EBITDA $56-60M.","Q4 2023 outlook: revenue $255-265M, Center Margin $73-81M, Adjusted EBITDA $17-21M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-060505","json":"https://secwatch.observer/filing/0000950170-23-060505.json","markdown":"https://secwatch.observer/filing/0000950170-23-060505.md","text":"https://secwatch.observer/filing/0000950170-23-060505.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1845257/000095017023060505/0000950170-23-060505-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1845257/000095017023060505/lfst-20231108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T10:49:08.403863+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"174641376bb4b231c139951fdf8d89f261695011","claim":"LifeStance Health Group, Inc. reported the third quarter ended September 30, 2023 results: revenue $262.9 million, net income Net loss of $61.6 million. Guidance raised.","evidence_excerpt":"third quarter ended September 30, 2023. (All results compared to prior-year comparative period, unless otherwise noted) Q3 2023 Highlights and FY 2023 Outlook • Total revenue of $262.9 million increased $45.3 million or 21% compared to total revenue of $217.6 million • Total clinicians of 6,418 up 18%, a sequential net increase of 286 in the third quarter • Net loss of","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1845257/000095017023060505/0000950170-23-060505-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Revenue","value":"$262.9 million"},{"label":"Net income","value":"Net loss of $61.6 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}